Torsade de pointes episodes under treatment with selective serotonin reuptake inhibitors

Pharmacopsychiatry

Volumn 43, Issue 7, 2010, Pages 279-281

  Wenzel Seifert, K ^a   Wittmann, M ^a   Haen, E ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RISK FACTOR; SINUS RHYTHM; TORSADE DES POINTES;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LONG QT SYNDROME; MALE; RISK; SEROTONIN UPTAKE INHIBITORS; TORSADES DE POINTES;

EID: 78049442306     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0030-1263167     Document Type: Article

References (20)

1. Altmann D, Eggmann U, Ammann P. Medikamentös induzierte Verlängerung des QT-Intervalls. Wien Klin Wochenschr 2008 120 128-135
2. Appleby M, Mbewu A, Clarke B. Fluoxetine and ventricular rorsade is there a link? Int J Cardiol 1995 49 178-180
3. Astrom-Lilja C, Odeberg JM, Ekman E, et al. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Safety 2008 17 587-592
4. Blaschke D, Parwani AS, Huemer M, et al. Torsade de pointes during combined treatment with risperidone and citalopram. Pharmacopsychiatry 2007 40 294-295
5. Brugisser M, Bravo A, Bodner M. Medikamenten-assoziiertes Long-QT-Syndrom [Medication associated long QT syndrome]. Praxis 2009 98 1409-1415
6. de Gregorio C, Morabito G, Cerrito M, et al. Citalopram-induced long QT syndrome and torsade de pointes: Role for committant therapies and illnesses. Int J Cardiol 2009
7. Gupta A, Lawrence AT, Krishnan K, et al. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J 2007 153 891-899
8. Hayes B, Klein-Schwarz W, Clark R, et al. Comparison of toxicity of acute overdoses with citalopram and escitalopram. J Emerg Med 2008 39 44-48
9. Isbister GK, Bowe SL, Dawson A, et al. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2004 42 277-285
10. Jimmink A, Caminada K, Ng H, et al. Clinical toxicity of citalopram after acute intoxication with the sole drug or in combination with other drugs: overview of 26 cases. Ther Drug Monit 2008 30 365-371
11. Kanjanauthai S, Kanluen T, Charreonthaitawee P. Citalopram induced torsade de pointes, a rare life threatening side effect. Int J Cardiol 2009 131 333-334
12. Lherm T, Lottin F, Larbi D, et al. [Torsades de pointes after poisoning with fluoxetine alone]. Presse Med 2000 29 306-307 (in French)
13. Meuleman C, Jourdain P, Bellorini M, et al. Citalopram et torsades de pointes: A propos d'un cas [citalopram and torsades de pointes: A case report]. Archives des maladies du coeur et des vaisseaux 2001 94 1021-1024 (in French)
14. Sala M, Coppa F, Cappuciati C, et al. Antidepressants: Their effects on cardiac channels, QT prolongation and torsade de pointes. Curr Opin Investigational Drugs 2006 7 256-263
15. Tarabar A, Hoffman R, Nelson L. Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest. J Med Toxicol 2008 4 101-105
16. van Gorp F, Whyte I, GK I. Clinical and ECG effects of escitalopram overdose. Ann Emerg Med 2009 54 404-408
17. van Noord C, Straus SMJM, Sturkenboom MCJM, et al. Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacology 2009 29 9-15
18. Wilting I, Samals OM, Holwerda NJ, et al. QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine. Am J Psychiatry 2006 163 325
19. Witchel H, Pabbathi V, Hofmann G, et al. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular calcium currents. FEBS Lett 2002 512 59-66
20. Woosley RL. Arizona CERT QT Drug Lists by Risk Groups (accessed 10.6.2010), at. http://www.azcert.org/med-prosl.cfm